Epstein Becker Green (EBG) conducted regulatory due diligence of a drug manufacturing business for a private equity transaction. EBG’s diligence assessed regulatory matters falling under the Food and Drug Administration, the Drug Enforcement Administration, and U.S. state-controlled substance and drug distribution laws. We also assembled an international team to advise on international regulatory matters. We supported the negotiation of regulatory terms in the purchase agreement, advised on the impact of deal structure on regulatory matters, and supported post-signing transition activities concerning necessary applications and powers of attorney related to continued operations after closing.
Results may vary depending on your particular facts and legal circumstances.
People
- Chair—Board of Directors / Member of the Firm
- Member of the Firm
- Member of the Firm
- Senior Counsel
- Member of the Firm